<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02182349</url>
  </required_header>
  <id_info>
    <org_study_id>1220.33</org_study_id>
    <nct_id>NCT02182349</nct_id>
  </id_info>
  <brief_title>Metabolism and Pharmacokinetics of Oral Solution of [14C]-BI 201335 in Healthy Male Volunteers</brief_title>
  <official_title>Metabolism and Pharmacokinetics of a Single Dose of 240 mg [14C]-BI 201335 Given as Oral Solution to Healthy Male Volunteers at Steady State of BI 201335 NA Maintained With Oral Capsules of 240 mg BI 201335, a Phase I, Single-arm, Open-label Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to determine the pharmacokinetics (PK) of BI 201335 and total radioactivity including
      excretion mass balance, excretion pathways and metabolism following the oral administration
      of [14C]-BI 201335 at steady state.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Individual concentration-time profiles of [14C]-radioactivity in whole blood, plasma, saliva, urine, and faeces</measure>
    <time_frame>up to 28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Individual concentration-time profiles of BI 201335 ZW in plasma and urine</measure>
    <time_frame>up to 28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate and extent of excretion mass balance based on the total radioactivity in urine and faeces</measure>
    <time_frame>up to 28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Elucidation of metabolite structures and identification of major metabolites in urine, faeces, and plasma in comparison with various animal species</measure>
    <time_frame>up to 28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cblood cell/Cplasma ratio of [14C]-radioactivity</measure>
    <time_frame>up to 28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of the plasma protein binding of total [14C]-radioactivity in human plasma samples ex vivo</measure>
    <time_frame>up to day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,ss (maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ)</measure>
    <time_frame>up to day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>tmax,ss (time from last dosing to maximum concentration of the analyte in plasma at steady state)</measure>
    <time_frame>up to day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmin,ss (minimum concentration of the analyte in plasma at steady state over a uniform dosing interval τ)</measure>
    <time_frame>up to day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCτ,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ)</measure>
    <time_frame>up to day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>λz,ss (terminal rate constant of the analyte in plasma at steady state)</measure>
    <time_frame>up to day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2,ss (terminal half-life of the analyte in plasma at steady state)</measure>
    <time_frame>up to day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>MRTpo,ss (mean residence time of the analyte in the body at steady state after oral administration)</measure>
    <time_frame>up to day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F,ss (apparent clearance of the analyte in the plasma at steady state following multiple oral dose administration)</measure>
    <time_frame>up to day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vz/F,ss (apparent volume of distribution of the analyte during the terminal phase λz at steady state following oral administration)</measure>
    <time_frame>up to day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ae,urine,0-tz,ss (amount of analyte that is eliminated in urine at steady state from the time point 0 to time point tz)</measure>
    <time_frame>up to day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>fe,urine,t1-t2,ss (fraction of the analyte in % of dose that is eliminated in urine at steady state from the time point 0 to time point tz)</measure>
    <time_frame>up to day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ae,feces,t1-t2,ss (fraction of the analyte that is eliminated in faeces at steady state from time point 0 to time point tz)</measure>
    <time_frame>up to day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>fe,feces,0-tz,ss (fraction of the analyte eliminated in faeces at steady state from time point 0 to time point tz)</measure>
    <time_frame>up to day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CLR,t1-t2,ss (renal clearance of the analyte at steady state from the time point 0 to time point tz)</measure>
    <time_frame>up to day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with abnormal findings in physical examination</measure>
    <time_frame>Baseline and day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically significant changes in vital signs (blood pressure, pulse rate)</measure>
    <time_frame>Baseline, day 1, 10, 16 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically significant changes in 12-lead electrocardiogram (ECG)</measure>
    <time_frame>Baseline, day 1, 10, 16 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically significant changes in clinical laboratory tests (haematology, clinical chemistry, urinalysis)</measure>
    <time_frame>Baseline, day 10 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of tolerability on a 4-point scale by the investigator</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BI 201335 NA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>multiple doses of BI 201335 NA soft gelatin capsule on days 1-8 and 11-15 and one single dose of [14C]-BI 201335 NA radiolabelled drug on day 9</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 201335 NA soft gelatin capsule</intervention_name>
    <arm_group_label>BI 201335 NA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C]-BI 201335 NA radiolabelled drug</intervention_name>
    <arm_group_label>BI 201335 NA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males according to a complete medical history, including a physical
             examination, vital signs (blood pressure, pulse rate), 12-lead ECG
             (electrocardiogram), and clinical laboratory tests

          -  Age 18 to 55 years, inclusive

          -  Body mass index 18.5 to 29.9 kg/m2, inclusive

          -  Nonsmoker

          -  Signed and dated written informed consent prior to admission to the study in
             accordance with GCP (Good Clinical Practice) and the local legislation

        Exclusion Criteria:

          -  Any finding in the medical examination (including blood pressure, pulse rate and ECG)
             deviating from normal and of clinical relevance

          -  Any evidence of a clinically relevant concomitant disease

          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological, hormonal, psychiatric or neurological disorders (including all forms of
             epilepsy)

          -  Surgery of the gastrointestinal tract (except appendectomy)

          -  History of relevant orthostatic hypotension, fainting spells or blackouts

          -  Subjects with Gilbert's Syndrome

          -  Chronic or relevant acute infections

          -  History of relevant allergy/hypersensitivity (including allergy to drug or its
             excipients)

          -  Intake of drugs with a long half-life (&gt;24 hours) within one month prior to
             administration of the trial drug

          -  Use of prescription medication, over-the-counter drugs or herbal preparations within
             14 days prior to administration of the trial drug

          -  Participation in another trial with an investigational drug within two months prior to
             administration of the trial drug or during the trial

          -  History or evidence of habitual tobacco or nicotine use within six months prior to
             administration of the trial drug

          -  Alcohol abuse (more than 2 ounces of alcohol/day)

          -  Drug abuse in opinion of investigator

          -  Blood donation (more than 100 mL within four weeks prior to administration of trial
             drug or during the trial)

          -  Excessive physical activity within five days prior to administration of trial drug

          -  Any laboratory value outside the reference range that is of clinical relevance

          -  Inability to comply with dietary regimen of trial centre

          -  marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc
             interval &gt;450 ms)

          -  Male subjects must agree to minimise the risk of female partners becoming pregnant
             from the dosing day until three months after the completion of the study. Acceptable
             methods of contraception for male volunteers include a vasectomy no less than three
             months prior to dosing, barrier contraception, or a medically accepted contraceptive
             method. For female partners of male volunteers, acceptable methods of contraception
             include intrauterine device, tubal ligation, hormonal contraceptive for at least two
             months, or diaphragm with spermicide

          -  Participation in more than one other radiolabelled investigational drug trial within
             one year prior to administration of the trial drug. The previous radiolabelled trial
             drug must have been received more than six months prior to administration of the trial
             drug for this study, and the total exposure from this study and the previous study
             will be within the recommended levels considered safe (e.g., less than 5000 mrem whole
             body annual exposure)

          -  Irregular defecation pattern (less than one bowel movement a day)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2014</study_first_submitted>
  <study_first_submitted_qc>July 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2014</study_first_posted>
  <last_update_submitted>July 17, 2014</last_update_submitted>
  <last_update_submitted_qc>July 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

